This company listing is no longer active
B6E0 Stock Overview
An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Swedish Orphan Biovitrum AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 13.30 |
| 52 Week High | SEK 14.10 |
| 52 Week Low | SEK 10.20 |
| Beta | 0.24 |
| 1 Month Change | 0% |
| 3 Month Change | 2.31% |
| 1 Year Change | 25.47% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 61.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| B6E0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.3% | 0.3% |
| 1Y | 25.5% | -14.0% | 6.9% |
Return vs Industry: B6E0 exceeded the German Biotechs industry which returned -16.5% over the past year.
Return vs Market: B6E0 exceeded the German Market which returned 9% over the past year.
Price Volatility
| B6E0 volatility | |
|---|---|
| B6E0 Average Weekly Movement | 3.9% |
| Biotechs Industry Average Movement | 7.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: B6E0 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: B6E0's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1939 | 1,814 | Guido Oelkers | www.sobi.com |
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra.
Swedish Orphan Biovitrum AB (publ) Fundamentals Summary
| B6E0 fundamental statistics | |
|---|---|
| Market cap | €9.24b |
| Earnings (TTM) | €305.68m |
| Revenue (TTM) | €2.21b |
30.2x
P/E Ratio4.2x
P/S RatioIs B6E0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| B6E0 income statement (TTM) | |
|---|---|
| Revenue | SEK 25.44b |
| Cost of Revenue | SEK 5.44b |
| Gross Profit | SEK 19.99b |
| Other Expenses | SEK 16.48b |
| Earnings | SEK 3.51b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 05, 2025
| Earnings per share (EPS) | 10.23 |
| Gross Margin | 78.60% |
| Net Profit Margin | 13.82% |
| Debt/Equity Ratio | 47.1% |
How did B6E0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/05 06:59 |
| End of Day Share Price | 2024/10/22 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Swedish Orphan Biovitrum AB (publ) is covered by 29 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alexander Lindström | ABG Sundal Collier |
| Rosie Turner | Barclays |
| Brian Balchin | Barclays |